Hematologic Malignancy
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Involving the Digestive System
CI-CAN-00002654Explore in graph →
Hematologic4 active trials
- NCIt
- C172844
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002654Explore in graph →
Clinical trials
6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
Showing 1–2 of 2 studies
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials